Bosutinib

Evidensnivå: L5 Förutsagda indikationer: 0 st

Innehållsförteckning

  1. Bosutinib
  2. BOSUTINIB: From Chronic Myeloid Leukaemia to Blast Phase CML, BCR-ABL1 Positive
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. Sweden Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Conclusion and Next Steps
    10. Ansvarsfriskrivning

## Apotekarens bedömningsrapport

Now I have all the context I need. The Evidence Pack's predicted_indications is empty, but the project's FHIR data shows a TxGNN prediction for "blast phase chronic myelogenous leukemia, BCR-ABL1 positive" with a score of 0.5. Let me generate the report.


BOSUTINIB: From Chronic Myeloid Leukaemia to Blast Phase CML, BCR-ABL1 Positive

One-Sentence Summary

Bosutinib is a BCR-ABL tyrosine kinase inhibitor originally developed for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase. The TxGNN model predicts it may also be effective for Blast Phase Chronic Myelogenous Leukaemia, BCR-ABL1 Positive, though with a moderate prediction score of 50%. Currently there are no clinical trials or publications included in the evidence pack to directly support this specific repurposing direction.

Quick Overview

Item Content
Original Indication Ph+ Chronic Myeloid Leukaemia (chronic phase)
Predicted New Indication Blast Phase Chronic Myelogenous Leukaemia, BCR-ABL1 Positive
TxGNN Prediction Score 50.00%
Evidence Level L5 (Model prediction only, no clinical studies in pack)
Sweden Market Status ✗ Not marketed
Number of Authorizations 0
Recommended Decision Hold

Why is This Prediction Reasonable?

Bosutinib is a dual Src/ABL tyrosine kinase inhibitor that blocks the constitutively active BCR-ABL1 fusion oncoprotein — the hallmark driver of chronic myeloid leukaemia. By inhibiting BCR-ABL1 kinase activity, bosutinib suppresses the proliferative signalling cascade that sustains the leukaemic clone. Globally, it is approved (as Bosulif®, Pfizer) for adult patients with newly diagnosed or resistant/intolerant Ph+ CML in the chronic phase.

Blast phase CML represents the terminal transformation of the disease, characterised by rapid expansion of immature blast cells and acquisition of additional genetic aberrations. Because the BCR-ABL1 fusion protein remains the central oncogenic driver even in blast crisis, a BCR-ABL1-directed inhibitor like bosutinib retains mechanistic plausibility. Indeed, other second- and third-generation TKIs (dasatinib, ponatinib) have demonstrated activity in blast phase CML, supporting the biological rationale.

However, blast phase CML is substantially more resistant to TKI monotherapy than chronic phase disease, due to clonal evolution, additional mutations (e.g. T315I for some TKIs), and activation of BCR-ABL1-independent survival pathways. The moderate TxGNN score of 50% may reflect this complexity. Detailed mechanism of action data was not available in the evidence pack; the above is based on the known pharmacological profile of bosutinib as a Src/ABL kinase inhibitor.

Clinical Trial Evidence

Trial Number Phase Status Enrollment Key Findings
Currently no related clinical trials registered in the evidence pack

Note: While the evidence pack contains no clinical trial data, bosutinib has been studied in blast phase CML in registration trials (e.g. the Phase 1/2 Study 200, NCT00261846) and has received FDA approval for Ph+ CML including accelerated phase. Additional targeted searches of ClinicalTrials.gov are recommended.

Literature Evidence

PMID Year Type Journal Key Findings
Currently no related literature available in the evidence pack

Note: Published data on bosutinib in advanced-phase CML exist in the medical literature (e.g. Cortes et al., Blood 2011; Gambacorti-Passerini et al., Am J Hematol 2015). A systematic literature search is recommended to supplement this evidence pack.

Sweden Market Information

Bosutinib is currently not marketed in Sweden and holds 0 authorizations from the Swedish MPA in this evidence pack.

Note: Bosutinib is authorised in the EU under the brand name Bosulif® (EMA centralised procedure). The absence of Swedish-specific license records may reflect data collection scope rather than true unavailability. Verification with the Swedish MPA / EMA EPAR database is recommended.

Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (BCR-ABL / Src tyrosine kinase inhibitor)
Myelosuppression Risk Moderate to High — thrombocytopenia, neutropenia, and anaemia are common (reported in >20% of patients in clinical trials)
Emetogenicity Classification Low to Moderate (nausea and diarrhoea are among the most frequent adverse events)
Monitoring Items CBC with differential (weekly during first month, then monthly); liver function tests (ALT, AST, bilirubin — hepatotoxicity risk); renal function (creatinine, eGFR); electrolytes; lipase (pancreatitis risk)
Handling Protection Standard oral targeted-therapy handling; no special cytotoxic spill precautions required beyond institutional policies for oral anticancer agents

Safety Considerations

Please refer to the package insert for safety information.

Key safety signals known from the global label (Bosulif® SmPC/USPI) include:

  • Hepatotoxicity: ALT/AST elevations reported; liver function monitoring required
  • Gastrointestinal toxicity: Diarrhoea (very common, may be severe), nausea, vomiting
  • Myelosuppression: Thrombocytopenia, neutropenia, anaemia
  • Fluid retention: Including pleural effusion, pericardial effusion, and peripheral oedema
  • Renal toxicity: Decline in eGFR observed; renal function monitoring recommended

The above is based on the globally known safety profile. The evidence pack did not contain TFDA/MPA-specific labelling data.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is moderate (50%), and the evidence pack currently contains no clinical trials, literature, or regulatory authorization data to support advancing this candidate. While the mechanistic rationale (BCR-ABL1 inhibition in blast phase CML) is sound and published literature outside this pack does exist, the evidence pack itself is at Level L5 with multiple critical data gaps.

To proceed, the following is needed:

  • Supplement the TxGNN prediction with a systematic literature search for bosutinib in blast phase / accelerated phase CML (PubMed, Cochrane)
  • Query ClinicalTrials.gov for completed and ongoing trials of bosutinib in advanced-phase CML
  • Obtain detailed MOA data from DrugBank API to close data gap DG002
  • Retrieve Swedish MPA / EMA authorization records for Bosulif® to clarify regulatory status in Sweden
  • Obtain package insert warnings and contraindications (FASS.se or EMA SmPC) to close data gap DG001
  • Re-evaluate the candidate once the evidence pack is supplemented; reclassification to Proceed with Guardrails is plausible if published Phase 2/3 data in blast phase CML are confirmed

    Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.



Back to top

Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.